

Antonio Silvani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4689367/publications.pdf>

Version: 2024-02-01

155
papers

4,768
citations

147726

31
h-index

114418

63
g-index

163
all docs

163
docs citations

163
times ranked

6539
citing authors

#	ARTICLE	IF	CITATIONS
1	Isocaloric Ketogenic Diet in Adults with High-Grade Gliomas: A Prospective Metabolic Study. <i>Nutrition and Cancer</i> , 2021, 73, 1004-1014.	0.9	8
2	Medulloblastoma of the adult: results from a multicenter retrospective study by AINO (Italian) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 707 42, 665-671.	0.9	5
3	Adult brainstem glioma: a multicentre retrospective analysis of 47 Italian patients. <i>Neurological Sciences</i> , 2021, 42, 1879-1886.	0.9	5
4	Neuro-telehealth for fragile patients in a tertiary referral neurological institute during the COVID-19 pandemic in Milan, Lombardy. <i>Neurological Sciences</i> , 2021, 42, 2637-2644.	0.9	18
5	Sustained Tumor Control With MAPK Inhibition in <i>BRAF</i> V600a Mutant Adult Glial and Clioneuronal Tumors. <i>Neurology</i> , 2021, 97, e673-e683.	1.5	16
6	Pathways of follow-up care in an Italian center: retrospective study on patients with gliomas II and III. <i>Neurological Sciences</i> , 2021, , 1.	0.9	3
7	Prospective observational study on the complications and tolerability of a peripherally inserted central catheter (PICC) in neuro-oncological patients. <i>Supportive Care in Cancer</i> , 2020, 28, 2789-2795.	1.0	9
8	Platypnea-orthodeoxia syndrome: an unusual cause of breathlessness in late pregnancy. <i>International Journal of Obstetric Anesthesia</i> , 2020, 44, 122-125.	0.2	0
9	Employment and Work Ability of Persons With Brain Tumors: A Systematic Review. <i>Frontiers in Human Neuroscience</i> , 2020, 14, 571191.	1.0	11
10	Gliomatosis cerebri (GC) or GC-like? A picture to be reconsidered in neuro-oncology based on large retrospective analysis of GC series. <i>Neurological Sciences</i> , 2020, 41, 2111-2120.	0.9	2
11	May we deliver neuro-oncology in difficult times (e.g. COVID-19)? <i>Journal of Neuro-Oncology</i> , 2020, 148, 203-205.	1.4	23
12	Italian consensus and recommendations on diagnosis and treatment of low-grade gliomas. An intersociety (SINch/AINO/SIN) document. <i>Journal of Neurosurgical Sciences</i> , 2020, 64, 313-334.	0.3	15
13	Biweekly fotemustine schedule for recurrent glioblastoma in the elderly: activity and toxicity assessment of a multicenter study. <i>CNS Oncology</i> , 2019, 8, CNS32.	1.2	5
14	P14.83 Adjuvant chemotherapy after severe myelotoxicity during temozolomide chemoradiation in gliomas. It is feasible? The talian Multicentric Study (AINO). <i>Neuro-Oncology</i> , 2019, 21, iii87-iii87.	0.6	1
15	Prognostic nutritional index as a prognostic marker in glioblastoma: Data from a cohort of 282 Italian patients. <i>Journal of the Neurological Sciences</i> , 2019, 400, 175-179.	0.3	16
16	Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 142, 455-462.	1.4	17
17	P14.64 Primary Central Nervous System Lymphoma (PCNSL) with HD- MTX based chemotherapy: tolerability and results. <i>Neuro-Oncology</i> , 2019, 21, iii82-iii82.	0.6	0
18	Stroke-like events after brain radiotherapy: a large series with long-term follow-up. <i>European Journal of Neurology</i> , 2019, 26, 639-650.	1.7	29

#	ARTICLE	IF	CITATIONS
19	Trabectedin for recurrent WHO grade II or III meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG).. Journal of Clinical Oncology, 2019, 37, 2007-2007.	0.8	13
20	Antiepileptic treatment and survival in newly diagnosed glioblastoma patients: Retrospective multicentre study in 285 Italian patients. Journal of the Neurological Sciences, 2018, 390, 14-19.	0.3	7
21	Anthropometrics and Body Composition in Adults with High-Grade Gliomas: Effects of Disease-Related Variables. Nutrition and Cancer, 2018, 70, 431-440.	0.9	5
22	PATH-31. GIANT CELL GLIOBLASTOMAS: ANALYSIS OF MISMATCH-REPAIR (MMR) PROTEINS EXPRESSION, POLIMERASE Îµ (POLE) MUTATIONS AND THEIR ROLE IN TUMOR IMMUNORESPONSE. Neuro-Oncology, 2018, 20, vi165-vi165.	0.6	1
23	IDH-wild type low grade gliomas: An AINO (Italian Association of Neuro-Oncology) retrospective study.. Journal of Clinical Oncology, 2018, 36, 2050-2050.	0.8	0
24	Effective long-term temozolomide rechallenge in a macroprolactinoma. Endocrinology, Diabetes and Metabolism Case Reports, 2018, 2018, .	0.2	2
25	Pattern of care and outcome in elderly patients with glioblastoma: Data in 151 patients from 3 Lombardia Hospitals. Journal of the Neurological Sciences, 2017, 378, 3-8.	0.3	13
26	Psychological features and quality of life in 50 adult patients with epilepsy and their caregivers from the Lecco epilepsy center, Italy. Epilepsy and Behavior, 2017, 71, 13-16.	0.9	11
27	Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma. Journal of Neuro-Oncology, 2017, 135, 545-552.	1.4	48
28	Extra central nervous system metastases from glioblastoma: a new possible trigger event?. Neurological Sciences, 2017, 38, 1873-1875.	0.9	9
29	Hidden reality: sexual sphere in brain tumor patients. Psychology, Health and Medicine, 2017, 22, 370-380.	1.3	9
30	Short Course Radiotherapy Concomitant with Temozolomide in GBM Patients: A Phase II Study. Tumori, 2017, 103, 457-463.	0.6	3
31	A case of medulloblastoma in adult patient affected by anaplastic oligoastrocytoma. Neurological Sciences, 2016, 37, 1727-1730.	0.9	2
32	Reversible Valproate Induced Pisa Syndrome and Parkinsonism in a Neuro-Oncology Patient with Depression and Epilepsy. Case Reports in Neurology, 2016, 8, 115-119.	0.3	3
33	Intrathecal synthesis of onconeural antibodies in patients with paraneoplastic syndromes. Journal of Neuroimmunology, 2016, 290, 119-122.	1.1	10
34	Safety and efficacy of primary central nervous system lymphoma treatment in elderly population. Neurological Sciences, 2016, 37, 131-133.	0.9	3
35	Does the duration of adjuvant temozolomide impact survival in glioblastoma patients? A retrospective analysis from an Italian registry (GLIOSTRY).. Journal of Clinical Oncology, 2016, 34, 2047-2047.	0.8	0
36	Caring for Brain Tumour Patients: Psychological Reactions After Bereavement. Journal of Palliative Care, 2015, 31, 97-102.	0.4	8

#	ARTICLE	IF	CITATIONS
37	Clinical management of grade III oligodendroglioma. <i>Cancer Management and Research</i> , 2015, 7, 213.	0.9	23
38	Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2535.	3.8	982
39	Headache in cerebral venous thrombosis associated with extracranial tumors: a clinical series. <i>Neurological Sciences</i> , 2015, 36, 149-151.	0.9	3
40	Radiosurgery reirradiation for high-grade glioma recurrence: a retrospective analysis. <i>Neurological Sciences</i> , 2015, 36, 1431-1440.	0.9	31
41	Cognitive strategies and quality of life of patients with high-grade glioma. <i>Supportive Care in Cancer</i> , 2015, 23, 3427-3435.	1.0	24
42	Herpes simplex encephalitis in glioma patients: a challenging diagnosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 374-377.	0.9	17
43	Tumor treating fields (TTFields): A novel treatment modality added to standard chemo- and radiotherapy in newly diagnosed glioblastoma—First report of the full dataset of the EF14 randomized phase III trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2000-2000.	0.8	16
44	GLIOSTRY (GLIOblastoma regiSTRY) of the AINO (Italian Association of Neuro-Oncology): Analysis of factors influencing survival in glioblastoma patients receiving the nitrosourea fotemustine at first relapse following Stupp regimen.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2054-2054.	0.8	0
45	ME-16 * IS AQUIPORIN4 (AQP4) INVOLVED IN ADULT HUMAN MEDULLOBLASTOMA DISSEMINATION OR IN A BENEFICIAL BARRIER FORMATION?. <i>Neuro-Oncology</i> , 2014, 16, v123-v123.	0.6	1
46	Safety of bevacizumab in patients with malignant gliomas: a systematic review. <i>Neurological Sciences</i> , 2014, 35, 83-89.	0.9	17
47	Update on treatment strategies for anaplastic glioma: a review of literature. <i>Neurological Sciences</i> , 2014, 35, 977-981.	0.9	14
48	Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010. <i>Neuro-Oncology</i> , 2014, 16, 719-727.	0.6	68
49	Quality of life and brain tumors: what beyond the clinical burden?. <i>Journal of Neurology</i> , 2014, 261, 894-904.	1.8	31
50	Safety of second-line chemotherapy with non-conventional fotemustine schedule in recurrent high grade gliomas: a single institution experience. <i>Journal of Neuro-Oncology</i> , 2013, 113, 527-529.	1.4	3
51	Short-course radiotherapy in elderly patients with glioblastoma: feasibility and efficacy of results from a single centre. <i>Strahlentherapie Und Onkologie</i> , 2013, 189, 456-461.	1.0	8
52	Liposomal cytarabine in neoplastic meningitis from primary brain tumors: a single institutional experience. <i>Neurological Sciences</i> , 2013, 34, 2151-2157.	0.9	13
53	Polycystic Lipomembranous Osteodysplasia with Sclerosing Leukoencephalopathy (PLOS�): A new report of an Italian woman and review of the literature. <i>Journal of the Neurological Sciences</i> , 2013, 326, 115-119.	0.3	20
54	Circulating T regulatory cells migration and phenotype in glioblastoma patients: an in vitro study. <i>Journal of Neuro-Oncology</i> , 2013, 115, 353-363.	1.4	24

#	ARTICLE	IF	CITATIONS
55	Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results. <i>Journal of Neurosurgery</i> , 2013, 118, 821-829.	0.9	26
56	Neoplastic Meningitis from Solid Tumors: A Prospective Clinical Study in Lombardia and a Literature Review on Therapeutic Approaches. <i>Journal of Drug Delivery</i> , 2013, 2013, 1-6.	2.5	3
57	Acute late-onset encephalopathy after radiotherapy: An unusual life-threatening complication. <i>Neurology</i> , 2013, 81, 1014-1017.	1.5	25
58	Decrease in circulating endothelial progenitor cells in treated glioma patients. <i>Journal of Neuro-Oncology</i> , 2012, 108, 123-129.	1.4	15
59	Recurrent brain tumour: the impact of illness on patient's life. <i>Supportive Care in Cancer</i> , 2012, 20, 1327-1332.	1.0	23
60	Brain tuberculoma (<i>Mycobacterium africanum</i>): high index of suspicion helps in avoiding biopsy/surgery. <i>Neurological Sciences</i> , 2012, 33, 363-365.	0.9	2
61	Adult medulloblastoma: multiagent chemotherapy with cisplatin and etoposide: a single institutional experience. <i>Journal of Neuro-Oncology</i> , 2012, 106, 595-600.	1.4	20
62	The burden of brain tumor: a single-institution study on psychological patterns in caregivers. <i>Journal of Neuro-Oncology</i> , 2012, 107, 175-181.	1.4	51
63	Combined chemotherapy with temozolomide and fotemustine in recurrent glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2011, 104, 617-618.	1.4	10
64	Malignant gliomas: early diagnosis and clinical aspects. <i>Neurological Sciences</i> , 2011, 32, 207-208.	0.9	12
65	Neuro-oncological diagnosis in patients without histological confirmation. <i>Neurological Sciences</i> , 2011, 32, 213-215.	0.9	1
66	Metabolic, electrolytes disorders and tromboembolic risk in malignant glioma patients. <i>Neurological Sciences</i> , 2011, 32, 229-231.	0.9	17
67	Loco-regional treatments in first-diagnosis glioblastoma: literature review on association between Stupp protocol and Gliadel. <i>Neurological Sciences</i> , 2011, 32, 241-245.	0.9	12
68	Rechallenge with temozolomide in recurrent glioma. <i>Neurological Sciences</i> , 2011, 32, 247-249.	0.9	5
69	Bevacizumab at recurrence in high-grade glioma. <i>Neurological Sciences</i> , 2011, 32, 251-253.	0.9	5
70	Lecture: fotemustine in brain tumors. <i>Neurological Sciences</i> , 2011, 32, 255-257.	0.9	45
71	Infections in neuro-oncology. <i>Neurological Sciences</i> , 2011, 32, 233-236.	0.9	6
72	Vitamin E neuroprotection for cisplatin neuropathy. <i>Neurology</i> , 2010, 74, 762-766.	1.5	174

#	ARTICLE	IF	CITATIONS
73	Intrathecal synthesis of tumor markers is a highly sensitive test in the diagnosis of leptomeningeal metastasis from solid cancers. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 874-9.	1.4	38
74	CXCL12, CXCR4 and CXCR7 expression in brain metastases. <i>Cancer Biology and Therapy</i> , 2009, 8, 1608-1614.	1.5	83
75	Neoplastic meningitis from breast carcinoma with complete response to liposomal cytarabine: case report. <i>Neurological Sciences</i> , 2009, 30, 251-254.	0.9	16
76	Cisplatin and BCNU chemotherapy in primary glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2009, 94, 57-62.	1.4	25
77	Systemic sagopilone (ZK-EPO) treatment of patients with recurrent malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2009, 95, 61-64.	1.4	22
78	Tumori cerebrali. , 2009, , 297-314.		0
79	Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients. <i>Journal of Neuro-Oncology</i> , 2008, 87, 143-151.	1.4	35
80	Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?. <i>Journal of Neuro-Oncology</i> , 2008, 88, 105-113.	1.4	42
81	Multicentre prospective collection of newly diagnosed glioblastoma patients: update on the Lombardia experience. <i>Neurological Sciences</i> , 2008, 29, 77-83.	0.9	8
82	Clinical and radiological features of brain neurotoxicity caused by antitumor and immunosuppressant treatments. <i>Neurological Sciences</i> , 2008, 29, 131-137.	0.9	30
83	Intracerebral haemorrhage in primary and metastatic brain tumours. <i>Neurological Sciences</i> , 2008, 29, 264-265.	0.9	9
84	Natural history and management of brainstem gliomas in adults. <i>Journal of Neurology</i> , 2008, 255, 171-177.	1.8	82
85	A phase II study evaluating systemic sagopilone (ZK-EPO) treatment in patients with recurrent malignant gliomas. <i>Journal of Clinical Oncology</i> , 2008, 26, 2083-2083.	0.8	4
86	Methylation of O6-Methylguanine DNA Methyltransferase and Loss of Heterozygosity on 19q and/or 17p Are Overlapping Features of Secondary Glioblastomas with Prolonged Survival. <i>Clinical Cancer Research</i> , 2007, 13, 2606-2613.	3.2	144
87	Methotrexate based chemotherapy and deferred radiotherapy for primary central nervous system lymphoma (PCNSL): single institution experience. <i>Journal of Neuro-Oncology</i> , 2007, 82, 273-279.	1.4	19
88	Brain metastases in patients receiving trastuzumab for breast cancer. <i>Neurological Sciences</i> , 2007, 28, 1-1.	0.9	14
89	Vitamin E in the neuroprotection of cisplatin induced peripheral neurotoxicity and ototoxicity. <i>Journal of Clinical Oncology</i> , 2007, 25, 9114-9114.	0.8	10
90	Tumour-associated epilepsy: clinical impact and the role of referring centres in a cohort of glioblastoma patients. A multicentre study from the Lombardia Neurooncology Group. <i>Neurological Sciences</i> , 2006, 27, 345-351.	0.9	32

#	ARTICLE	IF	CITATIONS
91	Reclassification of oligoastrocytomas by loss of heterozygosity studies. <i>International Journal of Cancer</i> , 2006, 119, 84-90.	2.3	51
92	Molecular markers of gliomas: a clinical approach. <i>Neurological Research</i> , 2006, 28, 538-541.	0.6	10
93	Prognostic value of CXCL12 expression in 40 low-grade oligodendrogliomas and oligoastrocytomas. <i>Cancer Biology and Therapy</i> , 2006, 5, 827-832.	1.5	35
94	Production and post-surgical modification of VEGF, tPA and PAI-1 in patients with glioma. <i>Cancer Biology and Therapy</i> , 2006, 5, 204-209.	1.5	9
95	Anaplasia Is Rare and Does Not Influence Prognosis in Adult Medulloblastoma. <i>Journal of Neuropathology and Experimental Neurology</i> , 2005, 64, 869-874.	0.9	22
96	Local drug delivery in recurrent malignant gliomas. <i>Neurological Sciences</i> , 2005, 26, s37-s39.	0.9	17
97	The role of the neurologist. <i>Neurological Sciences</i> , 2005, 26, s46-s48.	0.9	0
98	A multicentre prospective collection of newly diagnosed glioblastoma patients in Lombardia, Italy. <i>Neurological Sciences</i> , 2005, 26, 227-234.	0.9	12
99	Combined chemotherapy and radiotherapy for intracranial germinomas in adult patients: a single-institution study. <i>Journal of Neuro-Oncology</i> , 2005, 71, 271-276.	1.4	24
100	Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2005, 72, 125-131.	1.4	39
101	Expression of Drug Resistance Proteins Pgp, MRP1, MRP3, MRP5 AND GST- π in Human Glioma. <i>Journal of Neuro-Oncology</i> , 2005, 74, 113-121.	1.4	187
102	CXCL12 Expression is Predictive of a Shorter Time to Tumor Progression in Low-Grade Glioma: A Single-Institution Study in 50 Patients. <i>Journal of Neuro-Oncology</i> , 2005, 74, 287-293.	1.4	53
103	Systemic Temozolomide Combined with Loco-regional Mitoxantrone in Treating Recurrent Glioblastoma. <i>Journal of Neuro-Oncology</i> , 2005, 75, 215-220.	1.4	20
104	Facets and determinants of quality of life in patients with recurrent high grade glioma. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 562-568.	0.9	113
105	Genetic and Plasma Markers of Venous Thromboembolism in Patients with High Grade Glioma. <i>Clinical Cancer Research</i> , 2004, 10, 1312-1317.	3.2	90
106	Phase II Trial of Cisplatin Plus Temozolomide, in Recurrent and Progressive Malignant Glioma Patients. <i>Journal of Neuro-Oncology</i> , 2004, 66, 203-208.	1.4	64
107	CXCL12 in Malignant Glial Tumors: A Possible Role in Angiogenesis and Cross-Talk between Endothelial and Tumoral Cells. <i>Journal of Neuro-Oncology</i> , 2004, 67, 305-317.	1.4	72
108	Headache in brain tumours: a symptom to reappraise critically. <i>Neurological Sciences</i> , 2004, 25, s143-s147.	0.9	32

#	ARTICLE	IF	CITATIONS
109	Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. <i>Journal of Neuro-Oncology</i> , 2003, 62, 297-303.	1.4	131
110	Effects of thalidomide on parameters involved in angiogenesis: an in vitro study. <i>Journal of Neuro-Oncology</i> , 2003, 64, 193-201.	1.4	19
111	Poor metabolization of n-hexane in Parkinson's disease. <i>Journal of Neurology</i> , 2003, 250, 556-560.	1.8	13
112	Venous thromboembolism in malignant glioma patients treated by chemoradiotherapy. <i>Neurological Sciences</i> , 2003, 24, 272-272.	0.9	6
113	Local delivery of mitoxantrone for the treatment of malignant brain tumors in rats. <i>Journal of Neurosurgery</i> , 2003, 98, 935-6; author reply 936.	0.9	3
114	Association of chromosome 10 losses and negative prognosis in oligoastrocytomas. <i>Annals of Neurology</i> , 2002, 52, 842-845.	2.8	32
115	Intra-arterial ACNU and carboplatin versus intravenous chemotherapy with cisplatin and BCNU in newly diagnosed patients with glioblastoma. <i>Neurological Sciences</i> , 2002, 23, 219-224.	0.9	26
116	Temozolomide and cisplatin in the treatment of leptomeningeal metastatic involvement from melanoma: a case report. <i>Neurological Sciences</i> , 2002, 23, 257-258.	0.9	9
117	Fotemustine combined with procarbazine in recurrent malignant gliomas: a phase I study with evaluation of lymphocyte O6-alkylguanine-DNA alkyltransferase activity. <i>Journal of Neuro-Oncology</i> , 2001, 52, 149-156.	1.4	12
118	Efficacy of intratumoral delivery of mitoxantrone in recurrent malignant glial tumours. <i>Journal of Neuro-Oncology</i> , 2001, 54, 39-47.	1.4	21
119	Cisplatin and BCNU chemotherapy for anaplastic oligoastrocytomas. <i>Journal of Neuro-Oncology</i> , 2000, 49, 71-75.	1.4	9
120	Embryonal tumors in the adult population: implications in therapeutic planning. <i>Neurological Sciences</i> , 2000, 21, 23-30.	0.9	9
121	Interstitial chemotherapy plus systemic chemotherapy for glioblastoma patients: improved survival in sequential studies. <i>Journal of Neuro-Oncology</i> , 1999, 41, 151-157.	1.4	20
122	Safety and potential effectiveness of daunorubicin-containing liposomes in patients with advanced recurrent malignant CNS tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 43, 178-179.	1.1	14
123	Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 44, 173-176.	1.1	54
124	Chemotherapy is effective as early treatment for primary central nervous system lymphoma. <i>Journal of Neurology</i> , 1999, 246, 31-37.	1.8	25
125	Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients. <i>Italian Journal of Neurological Sciences</i> , 1999, 20, 43-48.	0.1	26
126	Tumor Necrosis Factor Microsatellite Polymorphisms in Italian Glioblastoma Patients. <i>Cancer Genetics and Cytogenetics</i> , 1999, 109, 172-174.	1.0	14

#	ARTICLE	IF	CITATIONS
127	Circulating intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and plasma thrombomodulin levels in glioblastoma patients. <i>Cancer Letters</i> , 1999, 146, 169-172.	3.2	22
128	New trends in the management of primary cerebral non-Hodgkin's lymphoma (PCNSL). <i>Italian Journal of Neurological Sciences</i> , 1998, 19, 53-54.	0.1	0
129	Transduction of the SkBr3 breast carcinoma cell line with the HOXB7 gene induces bFGF expression, increases cell proliferation and reduces growth factor dependence. <i>Oncogene</i> , 1998, 16, 3285-3289.	2.6	78
130	Radiotherapy at tumor recurrence in primary CNS lymphoma. <i>Neurology</i> , 1998, 50, 1934-1935.	1.5	8
131	Antineuronal Antibody in a Patient with Neuroblastoma and Opsoclonus-Myoclonus-Ataxia: A Case Report. <i>Tumori</i> , 1997, 83, 709-711.	0.6	8
132	Antineuronal Antibodies in Patients with Neuroblastoma: Relationships with Clinical Features. <i>Tumori</i> , 1997, 83, 953-957.	0.6	3
133	Advantage of treating anaplastic gliomas with aggressive protocol combining chemotherapy and radiotherapy. <i>Journal of Neuro-Oncology</i> , 1997, 34, 179-185.	1.4	25
134	Primary cerebral non-Hodgkin's lymphoma (PCNSL): a review of new trends in management. <i>Italian Journal of Neurological Sciences</i> , 1997, 18, 1-7.	0.1	5
135	Intrathecal immunotherapy in CNS tumors disseminating via CSF: preliminary evaluation using different treatment schedules. <i>Italian Journal of Neurological Sciences</i> , 1996, 17, 267-276.	0.1	4
136	Interstitial chemotherapy with mitoxantrone in recurrent malignant glioma: preliminary data. <i>Journal of Neuro-Oncology</i> , 1996, 27, 157-62.	1.4	21
137	In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab') ₂ bispecific monoclonal antibody. <i>British Journal of Cancer</i> , 1995, 72, 928-933.	2.9	30
138	Effectiveness of Early Chemotherapy Treatment in Anaplastic Astrocytoma Patients. <i>Tumori</i> , 1995, 81, 424-428.	0.6	1
139	Immunological Fluctuations During Intrathecal Immunotherapy in Three Patients Affected by CNS Tumours Disseminating Via CSF. <i>International Journal of Neuroscience</i> , 1994, 77, 117-125.	0.8	18
140	Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients. <i>Cancer Immunology, Immunotherapy</i> , 1994, 39, 193-197.	2.0	64
141	Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. <i>International Journal of Cancer</i> , 1994, 56, 853-857.	2.3	222
142	Characterization of an established human, malignant, glioblastoma cell line (GBM) and its response to conventional drugs. <i>Journal of Cancer Research and Clinical Oncology</i> , 1994, 120, 585-592.	1.2	27
143	Successful Adoptive Immunotherapy with Lymphokine-activated Killer Cells in the Treatment of Medulloblastoma Disseminated via Cerebrospinal Fluid. <i>Neurosurgery</i> , 1994, 34, 1078-1080.	0.6	19
144	Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients. <i>Cancer Immunology, Immunotherapy</i> , 1994, 39, 193-197.	2.0	7

#	ARTICLE	IF	CITATIONS
145	Chemotherapy as first treatment for primary malignant non-Hodgkin's lymphoma of the central nervous system preliminary data. <i>Journal of Neurology</i> , 1993, 241, 96-100.	1.8	37
146	Factors, including transforming growth factor β_2 , released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells. <i>Cancer Immunology, Immunotherapy</i> , 1993, 36, 409-416.	2.0	63
147	Efficacy of "8-drugs-in-one-day" combination in treatment of recurrent GBM patients. <i>Journal of Neuro-Oncology</i> , 1992, 12, 153-8.	1.4	16
148	Cisplatin neuropathy in brain tumor chemotherapy. <i>Italian Journal of Neurological Sciences</i> , 1992, 13, 311-315.	0.1	9
149	Carboplatin combined with carmustine and etoposide in the treatment of glioblastoma. <i>Italian Journal of Neurological Sciences</i> , 1992, 13, 717-722.	0.1	7
150	Neoadjuvant chemotherapy in the treatment of recurrent glioblastomas (GBM). <i>Italian Journal of Neurological Sciences</i> , 1992, 13, 583-588.	0.1	5
151	Natural history and postsurgical outcome of syringomyelia. <i>Italian Journal of Neurological Sciences</i> , 1991, 12, 575-579.	0.1	20
152	Local immunotherapy (β_2 -IFN) and systemic chemotherapy in primary glial tumors. <i>Italian Journal of Neurological Sciences</i> , 1991, 12, 163-168.	0.1	8
153	Cisplatin and etoposide combination therapy for primary glial tumors: Preliminary results. <i>Italian Journal of Neurological Sciences</i> , 1991, 12, 33-37.	0.1	1
154	Primary glial tumor patients treated by combining cis-platin and etoposide. <i>Journal of Neuro-Oncology</i> , 1991, 11, 165-170.	1.4	50
155	Neuron specific enolase (NSE) and thymidine kinase (TK) as markers in biological fluids of brain tumor patients. <i>Italian Journal of Neurological Sciences</i> , 1990, 11, 359-366.	0.1	1